Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

82 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase 2 study of the combination of gemcitabine and cisplatin in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines with/without taxanes.
Kohail H, Shehata S, Mansour O, Gouda Y, Gaafar R, Hamid TA, El Nowieam S, Al Khodary A, El Zawahry H, Wareth AA, Halim IA, Taleb FA, Hamada E, Barsoum M, Abdullah M, Meshref M. Kohail H, et al. Among authors: gaafar r. Hematol Oncol Stem Cell Ther. 2012;5(1):42-8. doi: 10.5144/1658-3876.2012.42. Hematol Oncol Stem Cell Ther. 2012. PMID: 22446614 Free article. Clinical Trial.
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.
Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou MF, Inbar M, Khaled H, Kielanowska J, Kwan WH, Mathew BS, Mittra I, Müller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Radhika R, Rajan B, Rubach MT, Tort S, Urrútia G, Valentini M, Wang Y, Peto R; Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group. Davies C, et al. Lancet. 2013 Mar 9;381(9869):805-16. doi: 10.1016/S0140-6736(12)61963-1. Lancet. 2013. PMID: 23219286 Free PMC article. Clinical Trial.
A phase II study of epirubicin in breast cancer.
el Mawla NG, Hamza MR, el Khodari A, Khaled H, Gaafar R, el Zawahry H, abdel Wareth A, Dardir MD, Habboubi N. el Mawla NG, et al. Among authors: gaafar r. Anticancer Drugs. 1991 Aug;2(4):371-4. doi: 10.1097/00001813-199108000-00006. Anticancer Drugs. 1991. PMID: 1797193 Clinical Trial.
Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication.
Miles D, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Campone M, Bondarenko I, Nowecki Z, Errihani H, Paluch-Shimon S, Wardley A, Merot JL, Trask P, du Toit Y, Pena-Murillo C, Revelant V, Klingbiel D, Bachelot T; PERUSE investigators. Miles D, et al. Ann Oncol. 2021 Oct;32(10):1245-1255. doi: 10.1016/j.annonc.2021.06.024. Epub 2021 Jul 2. Ann Oncol. 2021. PMID: 34224826 Free article. Clinical Trial.
Combination chemotherapy for advanced bilharzial bladder carcinoma.
Khaled HM, Gad el-Mawla N, el-Said A, Hamza MR, Gaafar R, el-Attar I, Abu Rabia A, Magrath I. Khaled HM, et al. Among authors: gaafar r. Ann Oncol. 1996 Sep;7(7):751-4. doi: 10.1093/oxfordjournals.annonc.a010727. Ann Oncol. 1996. PMID: 8905036 Free article. Clinical Trial.
82 results